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Background. Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coro-
navirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials.
Methods. This was the final day 28 comparative analysis of data from a phase 3, randomized, open-label study comparing 2 
remdesivir regimens (5 vs 10 days, combined for this analysis [remdesivir cohort]) and a real-world retrospective longitudinal co-
hort study of patients receiving standard-of-care treatment (nonremdesivir cohort). Eligible patients, aged ≥18 years, had confirmed 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), oxygen saturation ≤94% on room air or required supplemental 
oxygen, with pulmonary infiltrates. Propensity score matching (up to 1:10 ratio) was used to ensure comparable populations. We 
assessed day 14 clinical recovery (determined using a 7-point ordinal scale) and day 28 all-cause mortality (coprimary endpoints).
Results. A total of 368 (remdesivir) and 1399 (nonremdesivir) patients were included in the matched analysis. The day 14 clin-
ical recovery rate was significantly higher among the remdesivir versus the nonremdesivir cohort (65.2% vs 57.1%; odds ratio [OR], 
1.49; 95% confidence interval [CI], 1.16–1.90; P = 0.002). The day 28 mortality rate was significantly lower in the remdesivir cohort 
versus the nonremdesivir cohort (12.0% vs 16.2%; OR, 0.67; 95% CI, 0.47–.95; P = .03).
Conclusions. Remdesivir was associated with significantly higher rates of day 14 clinical recovery, and lower day 28 mortality, 
compared with standard-of-care treatment in hospitalized patients with COVID-19. These data, taken together, support the use of 
remdesivir to improve clinical recovery and decrease mortality from SARS-CoV-2 infection.
Keywords.  COVID-19; mortality; remdesivir; SARS-CoV-2.
The impact of the severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) global pandemic has been, and continues 
to be, significant [1]. Morbidity and mortality are considerable 
among older adults and those with comorbidities [2]. There 
has been an unprecedented global effort to develop strategies 
against SARS-CoV-2 infection, with ongoing trials assessing an-
tiviral, anti-inflammatory, and immunomodulatory treatments 
to be used alongside public health measures [3]. Efforts to iden-
tify effective treatments to complement accelerating vaccina-
tion programs remain a public health priority [4].
Remdesivir is a direct-acting nucleotide-analog pro-
drug that inhibits Coronaviridae ribonucleic acid (RNA)-
dependent RNA polymerase through incorporation of its 
triphosphate form into the viral RNA [5]. Remdesivir in-
hibits SARS-CoV-2 replication in vitro [6, 7], and accu-
mulating clinical evidence supports its use in patients with 
moderate or severe SARS-CoV-2 infection [8–12]. Data from 
a double-blind, randomized controlled trial indicated a re-
duced time to recovery in patients hospitalized with SARS-
CoV-2 infection receiving intravenous remdesivir for 10 days 
compared with placebo (median time to recovery 10  days 
[95% confidence interval {CI}, 9–11  days] vs 15  days [95% 
CI, 13–18  days]) [11]. Remdesivir was approved by the US 
Food and Drug Administration for use in hospitalized adults 
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and pediatric patients (≥12 years and weighing ≥40 kg) with 
SARS-CoV-2 infection and received conditional marketing 
authorization from the European Medicines Agency for use 
in patients with SARS-CoV-2-related pneumonia receiving 
supplemental oxygen.
The efficacy of remdesivir in patients with severe SARS-CoV-2 
infection was recently assessed in a comparative analysis of data 
from 2 studies: (1) a prospective phase 3, placebo-controlled, 
randomized study of remdesivir [8] and (2) a real-world ret-
rospective cohort study of patients receiving standard-of-care 
therapy [13]. In an interim analysis, day 14 clinical recovery 
(based on improvement on a 7-point ordinal scale) was re-
ported in 74.4% of patients in the remdesivir cohort compared 
with 59.0% in the nonremdesivir cohort (adjusted odds ratio 
[OR], 2.03; 95% CI, 1.34–3.08; P < .001) [13]. The secondary 
endpoint of day 14 mortality was lower in the remdesivir co-
hort versus the nonremdesivir cohort (7.6% vs 12.5%; adjusted 
OR, 0.38; 95% CI, 0.22–0.68; P = .001) [13]. In the final analysis, 
presented herein, after accrual of additional patients to allow for 
propensity matching, we describe the final results of this com-
parative study, the coprimary endpoints of day 14 clinical re-
covery, and day 28 all-cause mortality.
METHODS
The study design, patient populations, and endpoints from this 
comparative analysis have been described previously [13]. The 
prospective Study 5773 (Clinical trial: NCT04292899/GS-US-
540-5773) is a phase 3, randomized, open-label study conducted 
at 55 sites in the United States, Europe, and Asia [8]. The retro-
spective Study 5807 (Clinical trial: EUPAS34303/GS-US-540-
5807) was a real-world longitudinal cohort study conducted at 
32 sites in the United States, Europe, and Asia.
Patient Consent Statement
In prospective Study 5773, the protocol was approved by 
local institutional review boards or independent ethics com-
mittees, and the study was conducted in accordance with the 
principles of the Declaration of Helsinki and International 
Conference on Harmonisation Good Clinical Practice guide-
lines. In Study 5773, patients or their legally authorized rep-
resentative provided written informed consent or assent. 
Retrospective Study 5807 was conducted in compliance with 
Good Pharmacoepidemiology and Good Pharmacovigilance 
Practice. In Study 5807, patients or their legally authorized rep-
resentative provided written informed consent or assent for the 
use of deidentified secondary data as appropriate and when re-
quired by the regulations of the individual Institutional Review 
Boards. 
Patients
The inclusion criteria for patient enrollment in Study 5807 were 
designed to align with those in Study 5773 (described previously 
[8, 13]). Both studies enrolled patients with SARS-CoV-2 infec-
tion confirmed by polymerase chain reaction who had oxygen 
saturation ≤94% on room air or required supplemental oxygen 
and with radiographically confirmed pulmonary infiltrates (ie, 
patients with severe coronavirus disease 2019 [COVID-19]). 
Only patients aged ≥18  years were included in the current 
analysis.
To ensure comparability of patient populations, the exclusion 
criteria for prospective Study 5773 were retroactively applied 
to the retrospective Study 5807 population. Thus, patients were 
excluded from both studies if they had venoarterial extracor-
poreal membrane oxygenation on day 1; alanine transferase 
or aspartate transferase >5 × upper limit of normal; creatinine 
clearance <50  mL/min (Cockcroft-Gault formula); or were 
pregnant or breastfeeding. Patients were excluded from pro-
spective Study 5773 if they were receiving medication for the 
treatment of SARS-CoV-2 infection or mechanical ventilation 
at screening; however, patients enrolled in retrospective Study 
5807 were allowed to receive treatments for SARS-CoV-2 infec-
tion, excluding remdesivir. Between the interim and final ana-
lyses, an additional 2074 patients were enrolled in retrospective 
Study 5807 (including patients in Spain/Italy, data from which 
were not available for the interim analysis) to allow for the 
propensity-matched analysis.
Treatment
In prospective Study 5773, patients were randomized 1:1 to 
receive open-label remdesivir 200  mg on day 1 followed by 
remdesivir 100  mg/day either on days 2–5 or on days 2–10 
(randomization was 5 vs 10  days). All patients also received 
standard-of-care treatment (determined by local site prac-
tice). In the primary analysis of Study 5773, there was no sig-
nificant difference in efficacy or safety outcomes according to 
remdesivir treatment duration, and therefore data from both 
treatment arms were pooled for this comparative analysis [8]. 
In retrospective Study 5807, all patients received standard-of-
care treatment (nonremdesivir cohort) as determined by local 
treatment practices (except remdesivir, which was not approved 
for routine clinical use at the time of study).
Endpoints
The coprimary endpoints for retrospective Study 5807 final 
analysis were day 14 clinical recovery after initiation of treat-
ment and day 28 all-cause mortality. Clinical status was deter-
mined using a 7-point ordinal scale as previously described [13] 
(Table 1).
An earlier preplanned interim analysis reported change 
in day 14 clinical status (recovery) in the remdesivir and 
nonremdesivir cohorts and day 14 mortality rates [13]. The 
present report documents the final analysis based on com-
pleted data collection from additional patients and full 28-day 
follow-up.
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Statistical Analysis
Propensity score matching was used to form matched sets of 
patients from treated and control populations with similar 
propensity scores; no imputation was used in this analysis. 
Propensity scores were calculated using a logistic regression 
model to determine the probability of treatment assignment 
based on observed baseline characteristics as independent vari-
ables and treatment assignment (remdesivir vs no remdesivir) 
as the dependent variable. Baseline was defined as the start of 
remdesivir therapy in prospective Study 5773 and the date of 
hospitalization in retrospective Study 5807. Baseline factors in-
cluded in the propensity score model are summarized in Table 
2. See Supplementary Methods for further information on the 
propensity score matching. Recruitment for both studies was 
conducted before the results of the RECOVERY trial [14] and 
before the adoption of dexamethasone as part of standard of 
care in the clinic; thus, data on corticosteroid use were not col-
lected in Study 5807.
For the primary analysis, recovery and mortality rates were 
analyzed using a generalized estimating equation (GEE) lo-
gistic regression model including treatment as an independent 
variable and matched sets as clusters [15]. Additional ana-
lyses evaluated factors associated with day 28 mortality using a 
multivariable GEE logistic regression model; covariates used in 
the model are listed in Table 2.
A subgroup analysis of patients categorized according to ox-
ygen support status required at baseline (based on the 7-point 
ordinal scale) was conducted. The patient subgroups included 
those on invasive mechanical ventilation, high-flow oxygen 
(>6 L/min), low-flow oxygen (≤6 L/min), or room air (no sup-
plemental oxygen required). SAS version 9.4 (SAS Institute Inc., 
Cary, NC) was used.
RESULTS
Patients
The first patient’s initial visit in Study 5773 was on March 
6, 2020 and the last patient’s last visit was on April 27, 2020. 
The first patient enrolled in Study 5807 was hospitalized on 
February 6, 2020; data collection for Study 5807 was completed 
on May 15, 2020.
Of 397 patients who received remdesivir in Study 5773, 
368 were included in the final analysis set (remdesivir co-
hort), whereas 1399 (from 2710 available before matching) 
were included from Study 5807 (nonremdesivir cohort) 
(Supplementary Figure 1).
After matching, a notable difference between remdesivir 
and nonremdesivir cohorts was the receipt of medications 
for COVID-19 treatment (Supplementary Table 1). Before 
baseline, azithromycin use was higher in the remdesivir than 
nonremdesivir cohort (32.3% vs 19.0%). After matching, the 
factors used for the propensity score matching were generally 
well balanced. Table 3 summarizes baseline demographics and 
disease characteristics in the matched populations. Both co-
horts were broadly similar in terms of sex, age, race, and region 
of enrollment (Table 3). Comorbidities were also similar be-
tween treatment groups.
Coprimary Analyses: Day 14 Clinical Recovery and Day 28 Mortality
The day 14 clinical recovery rate was significantly higher in 
the remdesivir than nonremdesivir cohort (65.2% vs 57.1%; 
OR, 1.49; 95% CI, 1.16–1.90; P = .002) (Figure 1A). Day 28 
mortality was statistically significantly lower in the remdesivir 
than nonremdesivir cohort: 44 of 368 patients in the remdesivir 
cohort and 226 of 1399 in the nonremdesivir cohort had died 
(12.0% vs 16.2%; OR, 0.67; 95% CI, 0.47–0.95; P = .03) (Figure 
1B).
Subgroup and Multivariable Mortality Analyses
Day 14 recovery and day 28 mortality were evaluated after 
stratification for baseline oxygen requirement (Figure 2). 
The recovery rate was significantly higher for remdesivir-
treated patients on low-flow oxygen at baseline compared 
with the nonremdesivir cohort on low-flow oxygen, 78.6% 
versus 65.7%, respectively (OR, 2.00; 95% CI, 1.38–2.90; 
P = .0002). The mortality rate was significantly lower for 
Table 1. Ordinal Scale and Recovery Criteriaa
Ordinal Scale
1 Death
2 Hospitalized and receiving invasive mechanical ventilation or ECMO
3 Hospitalized and receiving noninvasive ventilation or high-flow oxygen
4 Hospitalized and requiring low-flow supplemental oxygen
5 Hospitalized and not requiring supplemental oxygen but receiving ongoing medical care
6 Hospitalized and not requiring supplemental oxygen or ongoing medical care
7 Not hospitalized
Recovery
Recovery was defined as a change in ordinal scale: from 2–4 to 5–7; or from 5 to 6–7; or from 6 to 7
Abbreviations: ECMO, extracorporeal membrane oxygenation.
aThe ordinal scale was a modified version from that used by Cao et al [36] and that proposed in the draft WHO R&D Blueprint COVID-19 Therapeutic Trial Synopsis [37]. If an ongoing hospi-
talized patient had missing clinical status at a visit, then the last available post-baseline clinical status before the visit with the missing value was used for that visit.
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remdesivir-treated patients on low-flow oxygen at base-
line compared with the nonremdesivir cohort on low-flow 
oxygen, 4.3% versus 12.5%, respectively (OR, 0.29; 95% 
CI, 0.14–0.58; P = .0005). No significant differences in re-
covery or mortality were identified between both cohorts 
for patients who were on room air or high-flow oxygen. No 
recovery or mortality benefit was apparent for patients on 
mechanical ventilation at baseline, although the number of 
patients in this subgroup was small.
To evaluate additional factors influencing survival, a 
multivariable analysis that included remdesivir treatment and 
other factors associated with COVID-19 outcomes was per-
formed. In the multivariable analysis, the OR for death by day 
28, comparing the remdesivir versus nonremdesivir cohort, was 
similar to the primary analysis (OR, 0.65; 95% CI, 0.44–0.96; 
P = .03) (Figure 3). This demonstrates that remdesivir treat-
ment reduces mortality after accounting for all the factors in-
cluded in the model. In addition (again, accounting for all the 
other factors in the model), a lower risk of death was associated 
with longer duration of symptoms before baseline, younger age, 
female sex, white race/ethnicity (vs black/African American), 
receiving a human immunodeficiency virus (HIV) protease 
inhibitor before or at baseline (where baseline was the start of 
remdesivir or date of hospitalization), not having cardiovas-
cular disease or chronic obstructive pulmonary disease, and 
being on room air or low-flow oxygen at baseline (vs invasive 
mechanical ventilation).
DISCUSSION
Treatment with remdesivir was associated with a significant 
reduction in the rate of day 28 all-cause mortality compared 
with standard-of-care treatment in patients hospitalized with 
COVID-19. In addition, the day 14 clinical recovery rate was 
significantly higher in the remdesivir cohort. Because surges 
in SARS-CoV-2 infections have pushed healthcare systems to 
the limits of their capacity in some countries, a beneficial effect 
of remdesivir treatment in shortening clinical recovery times 
could ease the burden on hospitals.
These findings represent the final analysis of a previously 
reported interim analysis [13]. There are several impor-
tant differences between the analyses. The present analysis 
used an increased population size in both the remdesivir and 
nonremdesivir groups, including >500 additional patients 
in the nonremdesivir cohort (818 in the interim/1399 in the 
final). The interim analysis used inverse probability of treat-
ment weighting, because sample size in the nonremdesivir co-
hort was insufficient for matching (at time of analysis). The final 
analysis included sufficient nonremdesivir patients to enable 
propensity score matching. Propensity score matching was able 
to balance baseline covariates and ensure comparable popula-
tions regarding characteristics that might influence clinical out-
come. In addition, patients from Italy and Spain were included 
in this analysis, further increasing global representation and 
generalizability (data unavailable for these patients at interim 
analysis). With the increased sample size and inclusion of ad-
ditional patients from Europe, the day 28 mortality benefit and 
the day 14 clinical recovery benefit were confirmed (coprimary 
endpoints).
Several studies have evaluated remdesivir for COVID-19. In 
our study, we found a clear mortality benefit with remdesivir, 
but randomized trials have not demonstrated this. A random-
ized clinical trial conducted in China failed to identify a statisti-
cally significant difference in time to clinical improvement with 
remdesivir versus placebo in patients with severe COVID-19 
(hazard ratio [HR], 1.23; 95% CI, 0.87–1.75) [12]. Day 28 mor-
tality was also not different between arms in that study (HR, 
1.1; 95% CI, −0.81 to 10.3). Notably, that study was underpow-
ered due to poor enrollment and early study closure [16]. The 
ACTT-1 study compared remdesivir (200 mg loading dose fol-
lowed by 100 mg daily for up to 9 additional days) with placebo 
in adults hospitalized with COVID-19 with evidence of lower 
respiratory tract infection [11]. Patients receiving remdesivir 
had a shorter time to recovery (defined as meeting the criteria 
Table 2. Baseline Factors Included in the Propensity Score Modela
Duration of symptoms before baseline
Clinical status using the 7-point ordinal scale score
Age (<40 years, 40–64 years, and ≥65 years)
Sex
Race (Asian, black, other, and white)
Country of enrollment (Italy, Spain, United States, other)
Obesity
Comorbidities (hypertension, cardiovascular disease, diabetes mellitus, COPD, asthma)
Investigational COVID-19 medications at the time of study design (azithromycin, biologics, HIV protease inhibitors, 
hydroxychloroquine, ribavirinb) taken at/before baseline
Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus.
aBaseline factors included in the propensity score model incorporated some of the sociodemographic factors and comorbidities outlined by the Centers for Disease Control and Prevention 
that may affect risk of severe illness [38].
bRibavirin was not included in the multivariable generalized estimating equation logistic regression model because the numbers were too low.
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for the top 3 categories on an 8-point ordinal scale) compared 
with those receiving placebo (median time to recovery, 10 
[95% CI, 9–11] vs 15 [95% CI, 13–18] days; rate ratio for re-
covery, 1.29 [95% CI, 1.12–1.49]; P < .001) [11]. In addition, 
patients receiving remdesivir were more likely to have clinical 
improvement at day 15 than those receiving placebo (OR, 1.5, 
95% CI,  1.2–1.9, after adjustment for disease severity). 
Consistent with the findings of the present analysis, Kaplan-
Meier mortality estimates with remdesivir versus placebo were 
6.7% versus 11.9% at day 15 (HR, 0.55; 95% CI, 0.36–0.83) and 
Table 3. Patient Demographics and Baseline Characteristics for the Matched Population (Based on Propensity Match Scoring) (Full Analysis Set)
Characteristic Remdesivir Cohort (n = 368) Nonremdesivir Cohort (n = 1399a)
Sex, n (%)
 Male 231 (62.8) 877 (62.7)
 Female 137 (37.2) 522 (37.3)
Age, mean (SD), years 59.7 (14.7) 60.5 (14.8)
Age range, n (%)
 <40 years 38 (10.3) 141 (10.1)
 40–64 years 178 (48.4) 683 (48.9)
 ≥65 years 152 (41.3) 574 (41.1)
Race
 White 251 (68.2) 949 (67.9)
 Asian 42 (11.4) 164 (11.7)
 Black or African American 43 (11.7) 171 (12.2)
 Other 32 (8.7) 115 (8.3)
Region
 United States 218 (59.2) 820 (58.6)
 Italy 66 (17.9) 247 (17.6)
 Spain 55 (15.0) 221 (15.8)
 Other 29 (7.9) 111 (7.9)
BMI, n (%)
 <30 kg/m2 210 (57.1) 821 (58.7)
 ≥30 kg/m2 158 (42.9) 578 (41.4)
Comorbidities, n (%)
 Hypertension 183 (49.7) 692 (49.5)
 Cardiovascular disease 103 (28.0) 365 (26.1)
 Diabetes mellitus 85 (23.1) 325 (23.2)
 Chronic obstructive pulmonary disease 17 (4.6) 71 (5.1)
 Asthma 46 (12.5) 181 (13.0)
Medications With Potential Activity Against COVID-19 Taken Before or at Baselineb, n (%)
 Azithromycin 119 (32.3) 426 (30.5)
 Biologicsc 16 (4.4) 52 (3.7)
 HIV protease inhibitor 36 (9.8) 139 (10.0)
 Hydroxychloroquine groupd 88 (23.9) 336 (24.0)
 Ribavirin 2 (0.5) 6 (0.4)
Baselineb Clinical Status on 7-Point Ordinal Scalee
 2 12 (3.3) 48 (3.4)
 3 94 (25.5) 351 (25.1)
 4 210 (57.1) 803 (57.4)
 5 52 (14.1) 197 (14.1)
Duration of symptoms, mean (SD), days 9.1 (3.8) 8.9 (5.7)
Baselineb ALT, mean (SD), U/L 43.0 (31.8) 42.5 (31.2) [n = 1274]
Baselineb AST, mean (SD), U/L 50.7 (28.7) [n = 362] 49.0 (28.8) [n = 1188]
eGFR, mean (SD), mL/min 114.3 (48.8) 103.9 (41.7) [n = 1267]
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; 
HIV, human immunodeficiency virus; SD, standard deviation.
aWeighted summary statistics.
bDefined as the start of remdesivir therapy in prospective Study 5773 (remdesivir cohort) and the date of hospitalization in retrospective Study 5807 (nonremdesivir cohort).
cBiologics included interferons, investigational biologics, plasma, sarilumab, siltuximab, and tocilizumab.
dHydroxychloroquine group included aminoquinolines, chloroquine, hydroxychloroquine, and hydroxychloroquine sulfate.
e2 = hospitalized and receiving invasive mechanical ventilation or extracorporeal membrane oxygenation; 3 = hospitalized and receiving noninvasive ventilation or high-flow oxygen; 
4 = hospitalized and requiring low-flow supplemental oxygen; 5 = hospitalized and not requiring supplemental oxygen but receiving ongoing medical care.
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11.4% versus 15.2% at day 29 (HR, 0.73; 95% CI, 0.52–1.03). The 
benefit of remdesivir was most apparent in patients receiving 
low-flow oxygen—consistent with the results of our subgroup 
























41/52 (78.9) 151/196 (77.1) 1.29 (0.61–2.75)
527/803 (65.7) 2.00 (1.38–2.90) P = .0002
P = .50
110/351 (31.4) 1.21 (0.74–1.99) P = .45
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Figure 2. Subgroup analysis of patients categorized according to oxygen support status required at baseline (based on propensity score matching) for (A) day 14 recovery 
and (B) day 28 all-cause mortality. P value, odds ratio, and 95% confidence interval (CI) were based on the generalized estimating equation logistic regression with matched 
sets considered as clusters. Numbers for the nonremdesivir cohort are based on weighted statistics.
Adjusted odds ratio: 1.49 
(95% CI: 1.16–1.90)
P = .002






























































Figure 1. Primary endpoint analyses: (A) odds ratio for day 14 clinical recovery; (B) odds ratio for day 28 all-cause mortality. P value, odds ratio, and 95% confidence interval 
(CI) were based on the generalized estimating equation logistic regression with propensity-matched sets considered as clusters. Numbers for the nonremdesivir cohort are 
based on weighted statistics. 
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mortality benefit of remdesivir for patients on low-flow oxygen 
at baseline, but no significant effect for patients who required 
high-flow oxygen or mechanical ventilation at baseline. The 
subgroup analysis suggests that initiating remdesivir early in 
the disease course (eg, for patients on low-flow oxygen) may 
provide the maximum benefit. Limited sample size precluded 
definitive analyses in other subgroups.
The Solidarity Therapeutics Trial, comparing remdesivir 
with local standard-of-care, also evaluated mortality and re-
ported a log-rank death rate ratio of 0.95 (95% CI, 0.81–1.11; 
P = .50; 301 of 2743 remdesivir vs 303 of 2708 control) [17]. 
Baseline oxygen status, other than mechanical ventilation, was 
not described in the Solidarity study. The subgroup of patients 
not on mechanical ventilation showed a rate ratio for death of 
0.86 (99% CI, 0.67–1.11), which was not significant but used an 
extremely conservative 99% CI. Commentators have suggested 
that Solidarity’s failure to detect a benefit with remdesivir may 
be due to variations across trial sites in standards of care, timing 
of treatment initiation, intensive care unit standards, and dis-
ease burden [18, 19].
The efficacy of remdesivir has also been evaluated for mod-
erate COVID-19 [20]. Compared with standard care, patients 
receiving a 5-day course of remdesivir had a significantly higher 
odds of a better clinical status distribution on day 11 (OR, 1.65; 
95% CI, 1.09–2.48; P = .02), whereas the clinical status distribu-
tion between the 10-day remdesivir and standard care groups 
was not significant (P = .18) [20], likely due to an interaction 
by open-label assignment resulting in a bimodal, rather than 
normal, distribution of date of hospital discharge. Real-world 
evidence supportive of remdesivir is also starting to accumu-
late, indicating that remdesivir could potentially have positive 
effects on clinical improvement and a favorable benefit/risk 
profile in different patient populations [9, 21, 22].
In light of the growing evidence base around pharmacolog-
ical interventions, remdesivir is recommended for COVID-
19 by the American Thoracic Society/European Respiratory 
Society Coordinated International Task Force [23], the National 
Institutes of Health [24], and the Infectious Diseases Society of 
America [25], as well as in several other national guidelines [3, 
26–32]. However, the World Health Organization currently 
has a conditional recommendation against administering 
remdesivir in addition to usual care [33]. Further studies are re-
quired to identify the optimal combinations of pharmacological 
agents for treatment regimens including remdesivir.
The multivariable analyses in this study were built upon 
the growing body of evidence on the factors influencing the 
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Figure 3. Multivariable analysis of the odds ratio for day 28 all-cause mortality using generalized estimating equation logistic regression model. *Medications potentially 
active against coronavirus disease 2019. CI, confidence interval; COPD, chronic obstructive pulmonary disease.
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survival of patients with severe COVID-19, with our model 
primarily aiming to investigate the robustness of the results 
of our primary analysis (ie, the treatment effect of remdesivir 
on mortality). The multivariable OR for treatment effect was 
comparable with the primary analysis, thereby confirming 
the treatment effect. In addition, the data suggested that after 
accounting for treatment arm, a lower risk of mortality was 
associated with the following: younger age, being female, 
being white (vs black/African American), being on low-flow 
oxygen or room air at baseline, receiving an HIV protease 
inhibitor before or at baseline, not having cardiovascular 
disease or chronic obstructive pulmonary disease, and (par-
adoxically) longer duration of symptoms before baseline. 
These results may differ from previous data in other pub-
lications [34–36] due to the nature of the cohorts and the 
analysis methods (including that our analysis was propen-
sity matched). As noted, however, the model confirmed that 
remdesivir reduces mortality after accounting for all factors 
in the model (including duration of symptoms, ethnicity, and 
other medications).
Strengths and limitations of the present analysis are as previ-
ously described [13]. In brief, strengths include the following: 
the remdesivir data are derived from a large, phase 3 study and 
detailed patient-level data were available for the nonremdesivir 
cohort; propensity score matching maximized comparability 
across treatment groups; and both studies ran in parallel, en-
suring consistent standard of care in both populations in the 
early days of the pandemic. In addition, the 28-day time point 
is reflective of the protracted course of the disease. Limitations 
include (1) the comparison of data from a prospective random-
ized study versus those from a retrospective, observational, 
nonrandomized treatment cohort, (2) that open-label treatment 
with remdesivir may be a source of bias (indeed, more patients 
in the nonremdesivir group received other medications with po-
tential activity against COVID-19), (3) potential residual con-
founding even after application of propensity score matching, 
and (4) that the use of unproven treatments for COVID-19 with 
potentially limited benefit (and potential harm) might have 
been more widespread in the nonremdesivir cohort. Finally, al-
though the benefits of systemic corticosteroid therapy among 
hospitalized patients with SARS-CoV-2 infection were demon-
strated in the RECOVERY trial [14], our study was conducted 
before those results. Thus, we did not capture corticosteroid use 
in the nonremdesivir cohort and could not evaluate the com-
bined impact of remdesivir with corticosteroids.
CONCLUSIONS
Remdesivir was associated with significantly higher rates 
of day 14 clinical recovery and lower day 28 mortality com-
pared with standard-of-care treatment in hospitalized patients 
with COVID-19. These data support the use of remdesivir to 
improve clinical recovery and lower mortality from SARS-
CoV-2 infection. In addition, by improving clinical recovery, 
remdesivir may help to reduce the burden on hospitals during 
surges in SARS-CoV-2 infections.
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